Release of endothelium-associated protein into blood by injection of heparin in normal subjects and in patients with Type 1 diabetes

Diabetic Medicine

Volumn 21, Issue 10, 2004, Pages 1135-1140

  Myrup, Bjarne ^a,d   Yokoyama, H ^a   Kristiansen, O P ^a   Ostergaard P B ^b   Olivecrona, T ^c  

^a STENO DIABETES CENTER   (Denmark)

^b Target Cell Biology   (Denmark)

^c UMEÅ UNIVERSITY   (Sweden)

^d Frederikssund Hospital   (Denmark)

Author keywords

Diabetic nephropathy; Heparan sulphate; Lipoprotein lipase; Tissue factor pathway inhibitor; Vitronectin

Indexed keywords

ANTITHROMBIN; FIBRONECTIN; HEPARAN SULFATE; LIPOPROTEIN LIPASE; LOW MOLECULAR WEIGHT HEPARIN; PROTEIN; SUPEROXIDE DISMUTASE; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; VITRONECTIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HUMAN; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PATHOGENESIS; PROTEIN DETERMINATION; PROTEIN SECRETION; PROTEINURIA; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ADULT; ANTICOAGULANTS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS; LIPOPROTEIN LIPASE; LIPOPROTEINS; MALE; MIDDLE AGED; PLATELET FACTOR 4; PROTEOGLYCANS; SUPEROXIDE DISMUTASE;

EID: 6344253118     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01313.x     Document Type: Article

References (28)

1. Deckert T, Kofoed-Enevoldsen A, Vidal P, Norgaard K, Andreasen HB, Feldt-Rasmussen B. Size- and charge-selectivity of glomerular filtration in Type 1 (insulin-dependent) diabetic patients with and without albuminuria. Diabetologia 1993; 36: 244-251.
2. Van den Born J, van den Heuvel LP, Bakker MA, Veerkamp JH, Assmann KJ, Berden JH. A monoclonal antibody against GBM heparan sulfate induces an acute selective proteinuria in rats. Kidney Int 1992; 41: 115-123.
3. Tamsma JT, Van Den BJ, Bruijn JA, Assmann KJ, Weening JJ, Berden JH. et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia 1994; 37: 313-320.
4. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987; 294: 1651-1654.
5. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1993; 32: 219-226.
6. Olivecrona T, Bengtsson G, Marklund S-E, Lindahl U, Höök M. Heparin-lipoprotein lipase interactions. Fed Proc 1977; 36: 60-65.
7. Iversen N, Sandset PM, Abildgaard U, Torjesen PA. Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans. Thromb Res 1996; 84: 267-278.
8. Karlsson K, Lindahl U, Marklund S. Binding of human extracellular Superoxide dismutase C to sulphated glycosaminoglycans. Biochem J 1988; 256: 29-33.
9. O'Brien JR, Etherington MD, Pashley MA. The heparin-mobilisable pool of platelet factor 4: a comparison of intravenous and subcutaneous heparin and Kabi heparin fragment 2165. Thromb Haemost 1985; 54: 735-738.
10. Naumnik B, Borawski J, Pawlak K, Mysliwiec M. Effect of hemodialysis on plasma levels of vascular endothelial markers. Clin Appl Thromb Hemost 2002; 8: 245-250.
11. Karlsson K, Marklund SL. Heparin-induced release of extracellular Superoxide dismutase to human blood plasma. Biochem J 1987; 242: 55-59.
12. Svendsen PA, Christiansen JS, Soegaard U, Welinder BS, Nerup J. Rapid changes in chromatographically determined haemoglobin A1c induced by short-term changes in glucose concentration. Diabetologia 1980; 19: 130-136.
13. Feldt-Rasmussen B, Dinesen B, Deckert M. Enzyme immunoassay: an improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 1985; 45: 539-544.
14. Yokoyama H, Myrup B, Rossing P, Ostergaard PB. Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy. Diabetes Care 1996; 19: 441-445.
15. Olivecrona T, Olivecrona G. Determination and clinical significance of lipoprotein lipase and hepatic lipase. In: Rifai, N, Warnick, GR, Dominiczak, MH, eds. Handbook of Lipoprotein Testing. Washington DC: AACC Press, 2000: 479-497.
16. Gram J, Jespersen J. Increased concentrations of heparin cofactor II in diabetic patients, and possible effects on thrombin inhibition assay for the measurement of antithrombin III. Clin Chem 1989; 35: 52-55.
17. Brown BW, Hollander M. Statistics. A Biomedical Introduction. New York: John Wiley & Sons, 1977: 333-335.
18. Edge AS, Spiro RG. A specific structural alteration in the heparan sulphate of human glomerular basement membrane in diabetes. Diabetologia 2000; 43: 1056-1059.
19. Elbert AE, Paglione AM, Bragagnolo JC, Mainetti HA, Bonavita CD, Ruiz M. Urinary heparan sulphate is increased in normoalbuminuric diabetic patients. Medicina (B Aires) 2000; 60: 195-201.
20. Preiss-Landl K, Zimmermann R, Hammerle G, Zechner R. Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. Curr Opin Lipidol 2002; 13: 471-481.
21. Lookene A, Chevreuil O, Ostergaard P, Olivecrona G. Interaction of lipoprotein lipase with heparin fragments and with heparan sulfate: stoichiometry, stabilization and kinetics. Biochemistry 1996; 35: 12155-12163.
22. Vilaro S, Llobera M, Bengtsson-Olivecrona G, Olivecrona T. Lipoprotein lipase uptake by the liver: localization, turnover, and metabolic role. Am J Physiol 1988; 254: G711-G722.
23. Ruge T, Svensson A, Eriksson JW, Olivecrona T, Olivecrona G. Food deprivation increases post-heparin lipoprotein lipase activity in humans. Eur J Clin Invest 2001; 31: 1040-1047.
24. Leurs PB, van Oerle R, Hamulyak K, Wolffenbuttel BHR. Tissue pathway inhibitor (TFPI) release after heparin stimulation is increased in type 1 diabetic patients with albuminuria. Diabetic Med 2003; 20: 16-22.
25. Seiffert D, Constitutive and regulated expression of vitronectin. Histol Histopathol 1997; 12: 787-797.
26. Niculescu F, Rus HG, Vlaicu R. Immunohistochemical localization of C5b-9, S-protein, C3d and apolipoprotein B in human arterial tissues with atherosclerosis. Atherosclerosis 1987; 65: 1-11.
27. Dufourcq P, Couffinhal T, Alzieu P, Daret D, Moreau C, Duplaa C et al. Vitronectin is up-regulated after vascular injury and vitronectin blockade prevents neointima formation. Cardiovasc Res 2002; 53: 952-962.
28. Preissner KT, Seiffert D. Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res 1998; 89: 1-21.